|
KAI Reports Positive Preclinical Results in Pain Therapeutic Program Targeting Gamma PKC Pathway |
October 20, 2009
|
|
Read more...
|
|
|
KAI Acquires Patents, Broadening KAI’s IP Estate Covering Peptide-Based Therapies |
June 30, 2009
|
|
Read more...
|
|
|
KAI Initiates Third Phase 2a Study to Develop KAI-1678 for the Treatment of Neuropathic Pain |
April 8, 2009
|
|
Read more...
|
|
|
KAI Expands KAI-1678 Development Program, Initiating a Phase 2a Study for Neuropathic Pain |
March 31, 2009
|
|
Read more...
|
|
|
KAI Pharmaceuticals Initiates Phase 2b Clinical Study of KAI-9803 in Heart Attack Patients |
December 17, 2008
|
|
Read more...
|
|
|
KAI-1678, First-in-Class Compound, Enters Phase 2a Clinical Testing for the Treatment of Pain |
December 10, 2008
|
|
Read more...
|
|
|
KAI Reports Positive Preclinical Results for KAI-1678 |
November 19, 2008
|
|
Read more...
|
|
|
KAI Pharmaceuticals Advances Third Product Candidate into Clinical Studies |
May 20, 2008
|
|
Read more...
|
|
|
Bristol-Myers Squibb and KAI Pharmaceuticals Enter Global Alliance |
May 13, 2008
|
|
Read more...
|
|
|
KAI Pharmaceuticals Initiates Phase 1 Trial of KAI-1455 for Ischemic Injury |
|
|
KAI Pharmaceuticals Presents Encouraging Phase 1/2 Results of a Novel Treatment for Heart Attack |
|
March 25, 2007
|
|
Read more...
|
|
|
KAI to Present KAI-9803 Phase I/II Trial Data in a Late-Breaking Session of the ACC |
|
February 7, 2007
|
|
Read more...
|
|
|
KAI Pharmaceuticals Appoints Dr. Dirk Mendel as Vice President, Pharmacology & Preclinical PK/PD |
|
November 7, 2006
|
|
Read more...
|
|
|
KAI Pharmaceuticals Completes $35 Million Series B Financing |
|
|
KAI Pharmaceuticals, Inc. and Sankyo Company, Ltd. Enter Global Alliance |
January 9, 2006
|
|
Read more...
|
|
|
KAI Pharmaceuticals Announces Appointment of Chief Medical Officer |
August 31, 2005
|
|
Read more...
|
|
|
KAI Pharmaceuticals Announces Appointments to Scientific Advisory Board |
July 1, 2005
|
|
Read more...
|
|
|
KAI Pharmaceuticals Announces Executive Appointments |
March 15, 2005
|
|
Read more...
|
|
|
KAI Pharmaceuticals Closes Series A Financing Round at $28 Million |
October 26, 2004
|
|
Read more...
|
|
|
KAI Pharmaceuticals Appoints Steven P. James as Chief Executive Officer |
October 19, 2004
|
|
Read more...
|
|
|
KAI Pharmaceuticals Initiates Phase I/II Clinical Trial for Treatment of Reperfusion Injury |
September 28, 2004
|
|
Read more...
|
|
